Quarterly Earnings

As Birchtech preps for its Q2 earnings, the market is watching. Its PFAS-fighting tech is promising, but can it fix a battered stock and prove its path to profit?

With spending up and losses widening, CG Oncology is leveraging its $1B cash reserve to push its promising bladder cancer drug toward a Q4 FDA submission.

Delcath Systems posts strong revenue and profits, but the real story is its massive investment in expanding its unique liver therapy to fight breast cancer and more.

The media giant posts a second straight profitable quarter, but a closer look reveals a strategy built on deep cuts and a shrinking user base.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

Tejon Ranch flipped a loss into a $2.6M profit by cutting costs and doubling down on industrial real estate. But is this disciplined focus enough to fund its massive future?

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

A stunning quarter for Establishment Labs shows a company moving from high-growth potential to high-growth reality, underpinned by strategic discipline.

Priority Technology reports impressive revenue growth, yet its GAAP profits are falling. A deep dive into the fintech's complex financials reveals its strategy.

Distribution Solutions Group announces a take-private deal with an 81% premium, fueled by strong earnings. A look at the strategy behind the move.

NexPoint thrives amid credit market turmoil by pairing cycle-resistant assets with a high-yield lending offensive, revealing a durable model for value creation.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

BlackSky posts a 50% revenue surge and positive earnings, proving its Gen-3 satellites and AI are mission-critical assets for government and global markets.

The pizza giant's North American sales are plummeting, forcing a drastic pivot. Can suspending shareholder payouts to fund a tech-heavy overhaul save it?

Genius Sports raises its outlook on soaring revenue post-acquisition, but a deeper look reveals widening losses. Can its strategic bet on data and media pay off?

With a return to profitability and digital revenue soaring, Lee Enterprises' Q3 results reveal a potent mix of financial strategy and digital transformation.

GPGI's Q2 results show a tale of two subsidiaries. While fintech darling CompoSecure hits records, industrial giant Husky faces market drag. Can one system steer both?

With a 32% jump in royalty revenue and a game-changing acquisition, Ligand Pharmaceuticals solidifies its market dominance. But is the growth sustainable?